AbbVie has launched its Produodopa therapy for Parkinson’s disease onto the market in the EU, becoming the first and only 24-hour levodopa-based subcutaneous infusion therapy for the ...
The final collaboration in 2008 was with San Francisco-based Exelixis to develop and commercialize two novel therapies: one for medullary thyroid cancer and the other as a treatment for advanced ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback